UroGen Pharma Ltd. Debt Securities, Available-for-sale, Amortized Cost
UroGen Pharma Ltd. (URGN) had Debt Securities, Available-for-sale, Amortized Cost of $28.84 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $28.84M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $30.30M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $9.69M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $37.35M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2026-06-30 | $28.84M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $30.30M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $9.69M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $37.35M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $68.68M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $96.36M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $69.66M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $129.06M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $21.34M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $33.12M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $46.46M 10-K · filed 2025-03-10 | |
| 2023-09-30 | $34.75M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $35.30M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $38.72M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $44.66M 10-K · filed 2024-03-14 | |
| 2022-09-30 | $67.38M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $31.77M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $31.81M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $45.48M 10-K · filed 2023-03-24 | $66.88M 10-K · filed 2022-03-21 |
| 2021-09-30 | $90.86M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $90.79M 10-Q · filed 2021-08-04 | |
| 2021-03-31 | $65.69M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $90.52M 10-K · filed 2022-03-21 | |
| 2020-09-30 | $103.75M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $135.47M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $147.95M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $162.67M 10-K · filed 2020-03-02 | |
| 2019-09-30 | $161.78M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $160.80M 10-Q · filed 2019-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |